Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Immunotherapy for the Treatment of Acute Leukemia

Publication Date: October 19, 2020

Last Updated: March 14, 2022

Recommendations

Diagnostics prior to immunotherapy for newly diagnosed patients with acute leukemia

Cell markers at diagnosis and at the time of disease relapse should be performed to identify potential markers that drugs can be used for treatment.

6731

Emerging immunotherapies for the treatment of patients with acute leukemia

Patients should be treated with FDA-approved therapies, if available, with clinical trial enrollment considered at each juncture.

6731

Overview

Title

Immunotherapy for the Treatment of Acute Leukemia

Authoring Organization